{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T09:13:55Z","timestamp":1648631635762},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2009,5,31]],"date-time":"2009-05-31T00:00:00Z","timestamp":1243728000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Heart Fail Rep"],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.1007\/s11897-009-0018-4","type":"journal-article","created":{"date-parts":[[2009,5,30]],"date-time":"2009-05-30T05:46:02Z","timestamp":1243662362000},"page":"117-125","source":"Crossref","is-referenced-by-count":2,"title":["Should aldosterone blockade be used beyond current indications in heart failure?"],"prefix":"10.1007","volume":"6","author":[{"given":"Marcelle D.","family":"Smit","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle C.","family":"van Gelder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"B\u00f6hm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans-Ruprecht","family":"Neuberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk J.","family":"van Veldhuisen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,5,31]]},"reference":[{"key":"18_CR1","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1161\/CIRCULATIONAHA.105.553370","volume":"112","author":"S.A. Hunt","year":"2005","unstructured":"Hunt SA, Abraham WT, Chin MH, et al.: ACC\/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005, 112:e154\u2013e235.","journal-title":"Circulation"},{"key":"18_CR2","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.ejheart.2008.08.005","volume":"10","author":"K. Dickstein","year":"2008","unstructured":"Dickstein K, Cohen-Solal A, Filippatos G, et al.: ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008, 10:933\u2013989.","journal-title":"Eur J Heart Fail"},{"key":"18_CR3","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00392-007-0487-y","volume":"96","author":"I.C. Horst Van der","year":"2007","unstructured":"Van der Horst IC, Voors AA, Van Veldhuisen DJ: Treatment of heart failure with ACE inhibitors and beta-blockers: what is next? Aldosterone receptor antagonists? Clin Res Cardiol 2007, 96:193\u2013195.","journal-title":"Clin Res Cardiol"},{"key":"18_CR4","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B. Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999, 341:709\u2013717.","journal-title":"N Engl J Med"},{"key":"18_CR5","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"B. Pitt","year":"2003","unstructured":"Pitt B, Remme W, Zannad F, et al.: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348:1309\u20131321. [Published erratum appears in N Engl J Med 2003, 348:2271.]","journal-title":"N Engl J Med"},{"key":"18_CR6","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0167-5273(00)00172-8","volume":"73","author":"A.C. Teisman","year":"2000","unstructured":"Teisman AC, Van Veldhuisen DJ, Boomsma F, et al.: Chronic beta-blocker treatment in patients with advanced heart failure. Effects on neurohormones. Int J Cardiol 2000, 73:7\u201312.","journal-title":"Int J Cardiol"},{"key":"18_CR7","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1161\/CIRCULATIONAHA.106.653964","volume":"115","author":"G. Guder","year":"2007","unstructured":"Guder G, Bauersachs J, Frantz S, et al.: Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure. Circulation 2007, 115:1754\u20131761.","journal-title":"Circulation"},{"key":"18_CR8","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s10557-006-8130-0","volume":"20","author":"O. Tsukamoto","year":"2006","unstructured":"Tsukamoto O, Minamino T, Sanada S, et al.: The antagonism of aldosterone receptor prevents the development of hypertensive heart failure induced by chronic inhibition of nitric oxide synthesis in rats. Cardiovasc Drugs Ther 2006, 20:93\u2013102.","journal-title":"Cardiovasc Drugs Ther"},{"key":"18_CR9","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1161\/01.HYP.0000203148.42892.7a","volume":"47","author":"N. Kobayashi","year":"2006","unstructured":"Kobayashi N, Yoshida K, Nakano S, et al.: Cardioprotective mechanisms of eplerenone on cardiac performance and remodeling in failing rat hearts. Hypertension 2006, 47:671\u2013679.","journal-title":"Hypertension"},{"key":"18_CR10","doi-asserted-by":"crossref","first-page":"H1802","DOI":"10.1152\/ajpheart.01096.2001","volume":"283","author":"R. Rocha","year":"2002","unstructured":"Rocha R, Rudolph AE, Frierdich GE, et al.: Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 2002, 283:H1802\u2013H1810.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"18_CR11","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1161\/01.HYP.0000203772.78696.67","volume":"47","author":"K. Nagata","year":"2006","unstructured":"Nagata K, Obata K, Xu J, et al.: Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats. Hypertension 2006, 47:656\u2013664.","journal-title":"Hypertension"},{"key":"18_CR12","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1210\/en.2004-0005","volume":"145","author":"M. Young","year":"2004","unstructured":"Young M, Funder JW: Eplerenone, but not steroid withdrawal, reverses cardiac fibrosis in deoxycorticosterone\/ salt-treated rats. Endocrinology 2004, 145:3153\u20133157.","journal-title":"Endocrinology"},{"key":"18_CR13","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3317\/jraas.2006.005","volume":"7","author":"W.C. Mello De","year":"2006","unstructured":"De Mello WC: Beneficial effect of eplerenone on cardiac remodelling and electrical properties of the failing heart. J Renin Angiotensin Aldosterone Syst 2006, 7:40\u201346.","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"18_CR14","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.cardfail.2004.02.010","volume":"10","author":"S. Masson","year":"2004","unstructured":"Masson S, Staszewsky L, Annoni G, et al.: Eplerenone, a selective aldosterone blocker, improves diastolic function in aged rats with small-to-moderate myocardial infarction. J Card Fail 2004, 10:433\u2013441.","journal-title":"J Card Fail"},{"key":"18_CR15","doi-asserted-by":"crossref","first-page":"R946","DOI":"10.1152\/ajpregu.00402.2006","volume":"292","author":"T. Ohtani","year":"2007","unstructured":"Ohtani T, Ohta M, Yamamoto K, et al.: Elevated cardiac tissue level of aldosterone and mineralocorticoid receptor in diastolic heart failure: Beneficial effects of mineralocorticoid receptor blocker. Am J Physiol Regul Integr Comp Physiol 2007, 292:R946\u2013R954.","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"18_CR16","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/j.1540-8167.2006.00372.x","volume":"17","author":"S.C. Shroff","year":"2006","unstructured":"Shroff SC, Ryu K, Martovitz NL, et al.: Selective aldosterone blockade suppresses atrial tachyarrhythmias in heart failure. J Cardiovasc Electrophysiol 2006, 17:534\u2013541.","journal-title":"J Cardiovasc Electrophysiol"},{"key":"18_CR17","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1093\/eurheartj\/ehi478","volume":"26","author":"P. Milliez","year":"2005","unstructured":"Milliez P, Deangelis N, Rucker-Martin C, et al.: Spironolactone reduces fibrosis of dilated atria during heart failure in rats with myocardial infarction. Eur Heart J 2005, 26:2193\u20132199.","journal-title":"Eur Heart J"},{"key":"18_CR18","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/S0002-9149(98)00092-7","volume":"81","author":"A.E. Tuinenburg","year":"1998","unstructured":"Tuinenburg AE, Van Veldhuisen DJ, Boomsma F, et al.: Comparison of plasma neurohormones in congestive heart failure patients with atrial fibrillation versus patients with sinus rhythm. Am J Cardiol 1998, 81:1207\u20131210.","journal-title":"Am J Cardiol"},{"key":"18_CR19","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.ejheart.2004.04.013","volume":"6","author":"A.D. Struthers","year":"2004","unstructured":"Struthers AD: The clinical implications of aldosterone escape in congestive heart failure. Eur J Heart Fail 2004, 6:539\u2013545.","journal-title":"Eur J Heart Fail"},{"key":"18_CR20","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/clc.4960291004","volume":"29","author":"B. Pitt","year":"2006","unstructured":"Pitt B, Ferrari R, Gheorghiade M, et al.: Aldosterone blockade in post-acute myocardial infarction heart failure. Clin Cardiol 2006, 29:434\u2013438.","journal-title":"Clin Cardiol"},{"key":"18_CR21","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1136\/hrt.2003.017368","volume":"90","author":"J.E. Macdonald","year":"2004","unstructured":"Macdonald JE, Kennedy N, Struthers AD: Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment. Heart 2004, 90:765\u2013770.","journal-title":"Heart"},{"key":"18_CR22","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1161\/CIRCULATIONAHA.105.571653","volume":"112","author":"H. Izawa","year":"2005","unstructured":"Izawa H, Murohara T, Nagata K, et al.: Mineralocorticoid receptor antagonism ameliorates left ventricular diastolic dysfunction and myocardial fibrosis in mildly symptomatic patients with idiopathic dilated cardiomyopathy: a pilot study. Circulation 2005, 112:2940\u20132945.","journal-title":"Circulation"},{"key":"18_CR23","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.jacc.2007.03.062","volume":"50","author":"A.K. Chan","year":"2007","unstructured":"Chan AK, Sanderson JE, Wang T, et al.: Aldosterone receptor antagonism induces reverse remodeling when added to angiotensin receptor blockade in chronic heart failure. J Am Coll Cardiol 2007, 50:591\u2013596.","journal-title":"J Am Coll Cardiol"},{"key":"18_CR24","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.cardfail.2006.01.013","volume":"12","author":"R.R. Baliga","year":"2006","unstructured":"Baliga RR, Ranganna P, Pitt B, Koelling TM: Spironolactone treatment and clinical outcomes in patients with systolic dysfunction and mild heart failure symptoms: a retrospective analysis. J Card Fail 2006, 12:250\u2013256.","journal-title":"J Card Fail"},{"key":"18_CR25","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1093\/eurjhf\/hfn015","volume":"11","author":"A. Boccanelli","year":"2009","unstructured":"Boccanelli A, Mureddu GF, Cacciatore G, et al.: Antiremodeling effect of canrenone in patients with mild chronic heart failure (AREA-IN-CHF Study): final results. Eur J Heart Fail 2009, 11:68\u201376.","journal-title":"Eur J Heart Fail"},{"key":"18_CR26","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.jacc.2007.01.091","volume":"49","author":"J.E. Udelson","year":"2007","unstructured":"Udelson JE, Feldman AM, Greenberg B, et al.: Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of eplerenone on ventricular remodeling in patients with left ventricular dysfunction and mild to moderate heart failure [abstract]. J Am Coll Cardiol 2007, 49:415\u2013417.","journal-title":"J Am Coll Cardiol"},{"key":"18_CR27","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1161\/01.CIR.0000138680.89536.A9","volume":"110","author":"P.M. Mottram","year":"2004","unstructured":"Mottram PM, Haluska B, Leano R, et al.: Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. Circulation 2004, 110:558\u2013565.","journal-title":"Circulation"},{"key":"18_CR28","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1016\/j.jacc.2004.11.070","volume":"45","author":"J.S. Healey","year":"2005","unstructured":"Healey JS, Baranchuk A, Crystal E, et al.: Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 2005, 45:1832\u20131839.","journal-title":"J Am Coll Cardiol"},{"key":"18_CR29","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1093\/eurheartj\/ehm341","volume":"28","author":"H.R. Neuberger","year":"2007","unstructured":"Neuberger HR, Mewis C, Van Veldhuisen DJ, et al.: Management of atrial fibrillation in patients with heart failure. Eur Heart J 2007, 28:2568\u20132577.","journal-title":"Eur Heart J"},{"key":"18_CR30","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jacc.2004.06.080","volume":"45","author":"K. Wachtell","year":"2005","unstructured":"Wachtell K, Hornestam B, Lehto M, et al.: Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005, 45:705\u2013711.","journal-title":"J Am Coll Cardiol"},{"key":"18_CR31","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ahj.2005.06.036","volume":"152","author":"A. Ducharme","year":"2006","unstructured":"Ducharme A, Swedberg K, Pfeffer MA, et al.: Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Am Heart J 2006, 152:86\u201392.","journal-title":"Am Heart J"},{"key":"18_CR32","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1161\/01.CIR.100.4.376","volume":"100","author":"O.D. Pedersen","year":"1999","unstructured":"Pedersen OD, Bagger H, Kober L, Torp-Pedersen C: Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 1999, 100:376\u2013380.","journal-title":"Circulation"},{"key":"18_CR33","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1136\/heart.86.5.527","volume":"86","author":"F. Pizzetti","year":"2001","unstructured":"Pizzetti F, Turazza FM, Franzosi MG, et al.: Incidence and prognostic significance of atrial fibrillation in acute myocardial infarction: the GISSI-3 data. Heart 2001, 86:527\u2013532.","journal-title":"Heart"},{"key":"18_CR34","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1161\/01.CIR.0000072793.81076.D4","volume":"107","author":"E. Vermes","year":"2003","unstructured":"Vermes E, Tardif JC, Bourassa MG, et al.: Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation 2003, 107:2926\u20132931.","journal-title":"Circulation"},{"key":"18_CR35","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S1071-9164(05)80004-1","volume":"1","author":"M.P. Berg Van den","year":"1995","unstructured":"Van den Berg MP, Crijns HJ, Van Veldhuisen DJ, et al.: Effects of lisinopril in patients with heart failure and chronic atrial fibrillation. J Card Fail 1995, 1:355\u2013363.","journal-title":"J Card Fail"},{"key":"18_CR36","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1093\/eurheartj\/ehl135","volume":"27","author":"Y. Yin","year":"2006","unstructured":"Yin Y, Dalal D, Liu Z, et al.: Prospective randomized study comparing amiodarone vs. amiodarone plus losartan vs. amiodarone plus perindopril for the prevention of atrial fibrillation recurrence in patients with lone paroxysmal atrial fibrillation. Eur Heart J 2006, 27:1841\u20131846.","journal-title":"Eur Heart J"},{"key":"18_CR37","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1161\/01.CIR.0000022665.18619.83","volume":"106","author":"A.H. Madrid","year":"2002","unstructured":"Madrid AH, Bueno MG, Rebollo JM, et al.: Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation 2002, 106:331\u2013336.","journal-title":"Circulation"},{"key":"18_CR38","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1016\/j.ehj.2003.08.014","volume":"24","author":"K.C. Ueng","year":"2003","unstructured":"Ueng KC, Tsai TP, Yu WC, et al.: Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study. Eur Heart J 2003, 24:2090\u20132098.","journal-title":"Eur Heart J"},{"key":"18_CR39","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0828-282X(08)70670-6","volume":"24","author":"M. Palardy","year":"2008","unstructured":"Palardy M, Ducharme A, Nattel S, et al.: Absence of protective effect of renin-angiotensin system inhibitors on atrial fibrillation development: insights from the Canadian Trial of Atrial Fibrillation (CTAF). Can J Cardiol 2008, 24:709\u2013713.","journal-title":"Can J Cardiol"},{"key":"18_CR40","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ijcard.2006.08.086","volume":"120","author":"A. Tveit","year":"2007","unstructured":"Tveit A, Grundvold I, Olufsen M, et al.: Candesartan in the prevention of relapsing atrial fibrillation. Int J Cardiol 2007, 120:85\u201391.","journal-title":"Int J Cardiol"},{"key":"18_CR41","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1471-2261-5-3","volume":"5","author":"T. Noord Van","year":"2005","unstructured":"Van Noord T, Crijns HJ, Van den Berg MP, et al.: Pretreatment with ACE inhibitors improves acute outcome of electrical cardioversion in patients with persistent atrial fibrillation. BMC Cardiovasc Disord 2005, 5:3.","journal-title":"BMC Cardiovasc Disord"}],"container-title":["Current Heart Failure Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-009-0018-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11897-009-0018-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-009-0018-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T20:09:52Z","timestamp":1559419792000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11897-009-0018-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5,31]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["18"],"URL":"https:\/\/doi.org\/10.1007\/s11897-009-0018-4","relation":{},"ISSN":["1546-9530","1546-9549"],"issn-type":[{"value":"1546-9530","type":"print"},{"value":"1546-9549","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,5,31]]}}}